All In MedTech

Device Trial Radar · NCT06386874

EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment

The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (the "EMAGINE 2.0" Study)

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

62

Actual

Start

Aug 20, 2024

Primary completion

Dec 26, 2025

Study completion Apr 7, 2026

Sponsor

Lead sponsor
BrainQ Technologies Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Apr 26, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Supportive care
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter study that will be conducted at approximately 20 centers and up to 30 centers, if the sample size will be increased following interim assessment. The Q Therapeutic System (BQ 3.0) is a wearable medical device that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. The Q Therapeutic System (BQ 3.0) is indicated for adjunctive use in a clinical facility or home setting, in addition to standard-of-care therapies. * In Stage 1 (starting 4-21 days after the index stroke event to day 90 post stroke), participants will be randomly assigned (1:1) to receive either active or the sham treatments, up to 5 times a week, and at least to a total of 45 treatments. * In Stage 2 (day 90 to day 180 post stroke), participants in both the active and the control group will be allowed to continue to receive active treatments, up to 5 times per week. * In stage 3 (day 180 to day 270 post stroke), participants will not receive any treatments and would be followed up until the final visit at day 270. Each session will last approximately 60 minutes, with stimulation activated for up to 40 minutes, in conjunction with a home-based exercise program. Treatments may be administered in the hospital, in the clinic or in a home setting. The study will enroll 100-122 adult subjects who will be randomly assigned (1:1 allocation ratio) to either active or sham study intervention using the BQ 3.0 system.

Conditions

  • Ischemic Stroke

Interventions

  • Q Therapeutic System (BQ 3.0) - ShamDevice

    The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. Frequency and intensity parameters will be set to zero so that no stimulation is delivered.

  • Q Therapeutic System (BQ 3.0) - ActiveDevice

    The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Modified Rankin ScaleTime frame: 4 to 21 days following an ischemic stroke to 90-day post-stroke

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Rancho Research Institute

    Downey, California

  • MedStar National Rehabililtaion Hospital,

    Washington D.C., District of Columbia

  • Brooks Rehabilitation Hospital

    Jacksonville, Florida

11 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.